These data supported our in vivo data showing that GLO1 activates eNOS by decreasing age-related eNOS (Thr495) phosphorylation and eNOS (Ser1177) dephosphorylation, resulting in increased NO bioavailability and amelioration of endothelial dysfunction. The gene discussed is NOS3; the disease is endothelial dysfunction.